MedX Health Rolls Out Teledermatology Screening Platform in U.K.

MedX Health Corp. continues to expand its teledermatology platform internationally.

The company has signed a U.K. commercialization pilot and distribution agreement for its DermSecure Screening platform with London Medical Laboratory Ltd. 

“This pilot is a critical first step to establishing our presence in a market of more than 68 million people. Given the increasing incidence rate of melanoma in the U.K., we will continue to seek additional opportunities to grow our presence throughout the U.K. and Ireland in the months to come,” said Naman Demaghlatrous, MedX managing director of Europe, Middle East and Africa. 

The pilot is scheduled to last three to six months and involve an estimated 1,000 patients in London. Upon completion, the MedX DermSecure Screening Platform will be made available at a number of new centers across the United Kingdom and Ireland. This agreement is the latest in a series of commercialization pilots recently launched across Europe and the Middle East as part of MedX’s global commercialization strategy, building on pilots underway in the Netherlands, Italy, Turkey and United Arab Emirates. Additional commercialization pilots are anticipated in the coming months.
 
“At London Medical Laboratory, we were seeking an innovative teledermatology partner for our patients and we found such a partner in MedX—their image capture system is the best available on the market today,” said Seth Rankin, CEO, London Medical Laboratory Ltd. “We look forward to working with MedX to make this leading technology available to the UK patients who need it most.”
 
Cancer Research UK estimates that melanoma skin cancer incidence rates have increased by 140 percent since the 1990s and has almost tripled for males during this time. The incidence rate is projected to grow an additional 7 percent by 2035, with approximately 16,700 new cases diagnosed each year. Early and rapid detection of melanoma is key to improving patient outcomes.

“With melanoma skin cancer rates more than doubling in the U.K. since the 1990s, our partnership with London Medical Laboratory presents an enormous opportunity to improve patient outcomes. Agreements like this ensure we can maximize our growth potential and realize our purpose of saving lives,” MedX CEO Sylvain Desjeans said. 
 
Teledermatology is a subspeciality of dermatology that offers safe and effective virtual care—patient screening and assessment—eliminating the need for in-person appointments with a dermatologist. MedX has developed high-definition image capture technology, SIAscopy, and a secure, cloud-based patient management system, DermSecure, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy is the only technology in the world that captures five high-resolution images of suspicious moles, lesions and skin conditions, including four spectrophotometric images 2mm below the skin’s surface. This technology provides detailed patient scans for virtual dermatological assessment by a certified dermatologist within just 72 hours.
 
Headquartered in Ontario, Canada, MedX is focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil, and Turkey.